PainReform Ltd. (NASDAQ:PRFX) Sees Significant Drop in Short Interest

by · The Cerbat Gem

PainReform Ltd. (NASDAQ:PRFX – Get Free Report) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 121,809 shares, a drop of 16.5% from the November 30th total of 145,963 shares. Based on an average daily volume of 217,670 shares, the days-to-cover ratio is presently 0.6 days. Currently, 9.2% of the shares of the company are sold short. Currently, 9.2% of the shares of the company are sold short. Based on an average daily volume of 217,670 shares, the days-to-cover ratio is presently 0.6 days.

Analysts Set New Price Targets

A number of brokerages have commented on PRFX. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research report on Wednesday, October 8th. Wall Street Zen raised PainReform from a “strong sell” rating to a “hold” rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on PRFX

PainReform Price Performance

Shares of NASDAQ:PRFX traded down $0.02 during trading on Wednesday, hitting $0.66. 42,536 shares of the company’s stock were exchanged, compared to its average volume of 1,440,690. PainReform has a 52-week low of $0.61 and a 52-week high of $6.65. The business’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.28. The company has a market cap of $1.32 million, a price-to-earnings ratio of 0.00 and a beta of 0.56.

PainReform (NASDAQ:PRFX – Get Free Report) last posted its quarterly earnings results on Wednesday, October 1st. The company reported ($0.55) EPS for the quarter.

About PainReform

(Get Free Report)

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.

Featured Articles